Optimizing Ex Vivo CAR-T Cell-Mediated Cytotoxicity Assay through Multimodality Imaging.

Area of Science:

• Oncology
• Immunotherapy
• Biotechnology

Background:

• CAR-T cell therapy shows promise for various cancers, particularly liquid tumors.
• Full human ex vivo assays are crucial for advancing precision CAR-T development.
• Existing cytotoxicity assays have limitations including radioactivity, lack of real-time data, and low throughput.

Purpose of the Study:

• To develop and optimize a novel multimodality imaging assay for evaluating CAR-T cell-mediated cytotoxicity.
• To overcome the limitations of current ex vivo CAR-T cell assays.
• To enhance the precision, reliability, and throughput of CAR-T cell efficacy testing.

Main Methods:

• Co-culture of CAR-T cells with CD19, CD20, and HER2 luciferase reporter cancer cells.
• Utilized multimodality imaging: bioluminescence, impedance tracking, phase contrast, and fluorescence.
• Real-time tracking of CAR-T cell interactions and cancer cell killing.
• Varied CAR-T cell to cancer cell ratios to optimize cytotoxicity readouts.

Main Results:

• The optimized assay successfully tracked CAR-T cells co-cultured with reporter cancer cells in real-time.
• Demonstrated effective CAR-T cell-mediated killing of target cancer cells.
• Provided superior temporal and spatial precision in measuring ex vivo CAR-T cytotoxicity.

Conclusions:

• The developed multimodality imaging assay is reliable, consistent, and high-throughput.
• This optimized assay significantly improves the evaluation of CAR-T cell efficacy in ex vivo settings.
• The assay supports precision CAR-T development and clinical evaluation for solid tumors.